Vani Lakshminarayanan

Vani Lakshminarayanan

Auto-generated profile, based on publicly available information

Vani Lakshminarayanan

Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic in Arizona, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
VLVani Lakshminarayanan
Vani Lakshminarayanan
PTPamela Thompson
Pamela Thompson
MWMargreet A. Wolfert
Margreet A. Wolfert
TBTherese Buskas
Therese Buskas
JBJudy M. Bradley
Judy M. Bradley
GBGeert-Jan Boons
Geert-Jan Boons
The mucin MUC1 is typically aberrantly glycosylated by epithelial cancer cells manifested by truncatedO-linked saccharides. The resultant glycopeptide epitopes can bind cell surface major histocompatibility complex (MHC) molecules and are susceptible to recognition by cytotoxic T lymphocytes (CTLs), whereas aberrantly glycosylated MUC1 protein on the tumor cell surface can be bound by antibodies to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Efforts to elicit CTLs and IgG antibodies against cancer-expressed MUC1 have not been successful when nonglycosylated MUC1 sequences were used for vaccination, probably due to conformational dissimilarities. Immunizations with densely glycosylated MUC1 peptides have also been ineffective due to impaired susceptibility to antigen processing. Given the challenges to immuno-target tumor-associated MUC1, we have identified the minimum requirements to consistently induce CTLs and ADCC-mediating antibodies specific for the tumor form of MUC1 resulting in a therapeutic response in a mouse model of mammary cancer. The vaccine is composed of the immunoadjuvant Pam3CysSK4, a peptide Thelperepitope and an aberrantly glycosylated MUC1 peptide. Covalent linkage of the three components was essential for maximum efficacy. The vaccine produced CTLs, which recognized both glycosylated and nonglycosylated peptides, whereas a similar nonglycosylated vaccine gave CTLs which recognized only nonglycosylated peptide. Antibodies elicited by the glycosylated tripartite vaccine were significantly more lytic compared with the unglycosylated control. As a result, immunization with the glycosylated tripartite vaccine was superior in tumor prevention. Besides its own aptness as a clinical target, these studies of MUC1 are likely predictive of a covalent linking strategy applicable to many additional tumor-associated antigens.

30 May 2014 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
VLVani Lakshminarayanan
Vani Lakshminarayanan
PTPamela Thompson
Pamela Thompson
NSNitin Supekar
Nitin Supekar
JBJudy M. Bradley
Judy M. Bradley
GBGeert‐Jan Boons
Geert‐Jan Boons

29 May 2015 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
PTPamela Thompson
Pamela Thompson
VLVani Lakshminarayanan
Vani Lakshminarayanan
NSNitin T. Supekar
Nitin T. Supekar
JBJudy M. Bradley
Judy M. Bradley
PCPeter A. Cohen
Peter A. Cohen
GBGeert-Jan Boons
Geert-Jan Boons
A strategically designed sialyl-Tn building block was synthesized in a stereospecific manner for the rapid linear construction of a glycolipopeptide cancer vaccine.

20 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VLVani Lakshminarayanan
Vani Lakshminarayanan
NSNitin T. Supekar
Nitin T. Supekar
JWJie Wei
Jie Wei
DMDustin B. McCurry
Dustin B. McCurry
ADAmylou C. Dueck
Amylou C. Dueck
SGSandra Gendler
Sandra Gendler
It remains challenging to produce decisive vaccines against MUC1, a tumor-associated antigen widely expressed by pancreas, breast and other tumors. Employing clinically relevant mouse models, we ruled out such causes as irreversible T-cell tolerance, inadequate avidity, and failure of T-cells to recognize aberrantly glycosylated tumor MUC1. Instead, every tested MUC1 preparation, even non-glycosylated synthetic 9mer peptides, induced interferon gamma-producing CD4+ and CD8+ T-cells that recognized glycosylated variants including tumor-associated MUC1. Vaccination with synthetic peptides conferred protection as long as vaccination was repeated post tumor challenge. Failure to revaccinate post challenge was associated with down-regulated tumor MUC1 and MHC molecules. Surprisingly, direct admixture of MUC1-expressing tumor with MUC1-hyperimmune T-cells could not prevent tumor outgrowth or MUC1 immunoediting, whereas ex vivo activation of the hyperimmune T-cells prior to tumor admixture rendered them curative. Therefore, surrogate T-cell preactivation outside the tumor bed, either in culture or by repetitive vaccination, can overcome tumor escape.

29 June 2016 in Biomolecules
Verified
Journal Article
Open access
PDF file
LPLatha Pathangey
Latha Pathangey
VLVani Lakshminarayanan
Vani Lakshminarayanan
VSVera Suman
Vera Suman
BPBarbara A. Pockaj
Barbara A. Pockaj
Pinku MukherjeePinku Mukherjee
Pinku Mukherjee
SGSandra Gendler
Sandra Gendler
Cancer vaccines have often failed to live up to their promise, although recent results with checkpoint inhibitors are reviving hopes that they will soon fulfill their promise. Although mutation-specific vaccines are under development, there is still high interest in an off-the-shelf vaccine to a ubiquitous antigen, such as MUC1, which is aberrantly expressed on most solid and many hematological tumors, including more than 90% of breast carcinomas. Clinical trials for MUC1 have shown variable success, likely because of immunological tolerance to a self-antigen and to poor immunogenicity of tandem repeat peptides. We hypothesized that MUC1 peptides could be optimized, relying on heteroclitic optimizations of potential anchor amino acids with and without tumor-specific glycosylation of the peptides. We have identified novel MUC1 class I peptides that bind to HLA-A*0201 molecules with significantly higher affinity and function than the native MUC1 peptides. These peptides elicited CTLs from normal donors, as well as breast cancer patients, which were highly effective in killing MUC1-expressing MCF-7 breast cancer cells. Each peptide elicited lytic responses in greater than 6/8 of normal individuals and 3/3 breast cancer patients. The CTLs generated against the glycosylated-anchor modified peptides cross reacted with the native MUC1 peptide, STAPPVHNV, suggesting these analog peptides may offer substantial improvement in the design of epitope-based vaccines.